DMAC Oct 2024 2.500 put
- Simply Wall St.
We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, although...
- Insider Monkey
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q1 2024 Earnings Call Transcript
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q1 2024 Earnings Call Transcript May 11, 2024 DiaMedica Therapeutics Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics First Quarter 2024 Conference Call. An […]
- Business Wire
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results
MINNEAPOLIS, May 08, 2024--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the quarter ended March 31, 2024. Management will host a conference call Thursday, May 9, 2024 at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and first quarter 2024 financial results.
